Unknown

Dataset Information

0

TGF?1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary chondrocytes and mediated by TAK1 kinase activity.


ABSTRACT: Dysregulated transforming growth factor ? (TGF?) signaling is implicated in osteoarthritis development, making normalizing TGF? signaling a possible therapy. Theoretically, this can be achieved with small molecule inhibitors specifically targeting the various TGF? receptors and downstream mediators. In this study we explore in primary chondrocytes the use of small molecule inhibitors to target TGF?-induced pSmad1/5/9-, pSmad2/3- and TGF?-activated kinase 1 (TAK1)-dependent signaling.Primary bovine chondrocytes and explants were isolated from metacarpophalangeal joints. To modulate TGF? signaling the activin receptor-like kinase (ALK)1/2/3/6 inhibitor LDN-193189, the ALK4/5/7 inhibitor SB-505124 and the TAK1 inhibitor (5Z)-7-Oxozeaenol were used. pSmad1/5 and pSmad2 were measured using western blot analysis and TGF?1-induced gene expression was measured using quantitative real time PCR (qPCR).In chondrocytes, TGF?1 strongly induced both pSmad1/5 and pSmad2. Remarkably, LDN-193189 did not inhibit TGF?-induced pSmad1/5. In contrast, SB-505124 did inhibit both TGF?-induced Smad2 and Smad1/5 phosphorylation. Furthermore, (5Z)-7-Oxozeaenol also profoundly inhibited TGF?-induced pSmad2 and pSmad1/5. Importantly, both SB-505124 and (5Z)-7-Oxozeaenol did not significantly inhibit constitutively active ALK1, making an off-target effect unlikely. Additionally, LDN-193189 was able to potently inhibit BMP2/7/9-induced pSmad1/5, showing its functionality. On gene expression, LDN-193189 did not affect TGF?1-induced regulation, whereas both SB-505124 and (5Z)-7-Oxozeaenol did. Similar results were obtained in cartilage explants, although pSmad1/5 was not strongly induced by addition of TGF?1.Our data suggest that ALK5 kinase activity plays a central role in both TGF?-induced Smad1/5 and Smad2/3 phosphorylation, making it difficult to separate both pathways with the use of currently available small molecule inhibitors. Furthermore, our data regarding (5Z)-7-Oxozeaenol suggest that TAK1 facilitates Smad-dependent signaling.

SUBMITTER: van Caam A 

PROVIDER: S-EPMC5452635 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary chondrocytes and mediated by TAK1 kinase activity.

van Caam Arjan A   Madej Wojciech W   Garcia de Vinuesa Amaya A   Goumans Marie-José MJ   Ten Dijke Peter P   Blaney Davidson Esmeralda E   van der Kraan Peter P  

Arthritis research & therapy 20170531 1


<h4>Background</h4>Dysregulated transforming growth factor β (TGFβ) signaling is implicated in osteoarthritis development, making normalizing TGFβ signaling a possible therapy. Theoretically, this can be achieved with small molecule inhibitors specifically targeting the various TGFβ receptors and downstream mediators. In this study we explore in primary chondrocytes the use of small molecule inhibitors to target TGFβ-induced pSmad1/5/9-, pSmad2/3- and TGFβ-activated kinase 1 (TAK1)-dependent sig  ...[more]

Similar Datasets

| S-EPMC2832549 | biostudies-literature
| S-EPMC2634733 | biostudies-literature
| S-EPMC8194238 | biostudies-literature
| S-EPMC4642318 | biostudies-literature
| S-EPMC2807291 | biostudies-literature
| S-EPMC9741628 | biostudies-literature
| S-EPMC3609023 | biostudies-literature
| S-EPMC1727626 | biostudies-other
| S-EPMC10823139 | biostudies-literature
| S-EPMC6819484 | biostudies-literature